EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach for Staphylococcus aureus In Vivo Infection

Samar Zuhair Alshawwa, Thanaa A El-Masry, Mohamed Nasr iD, Ahmed Y Kira iD, Hadil Faris Alotaibi iD, Al-Sayed Sallam iD, Engy Elekhnawy iD

Microorganisms · 06.09.2023 · 11 (9) · 2247

DOI: 10.3390/microorganisms11092247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microorganisms, online erschienen am 06.09.2023. Verfasst von Samar Zuhair Alshawwa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research at Princess Nourah bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a great need for novel approaches to treating bacterial infections, due to the vast dissemination of resistance among pathogenic bacteria. Staphylococcus aureus are ubiquitous Gram-positive pathogenic bacteria and are rapidly acquiring antibiotic resistance. Here, celecoxib was encapsulated into cubosomal nanoparticles, and the particle morphology, size distribution, zeta potential, entrapment efficiency, and celecoxib release were evaluated in vitro. Also, a systemic infection model in mice elucidated the in vivo antibacterial action of the celecoxib cubosomes. Cubosomes are a nanotechnology-based delivery system which can adhere to the external peptidoglycan layers of Gram-positive bacteria and penetrate them. The size distribution investigation revealed that the prepared celecoxib-loaded cubosomes had a mean particle size of 128.15 ± 3.04 nm with a low polydispersity index of 0.235 ± 0.023. The zeta potential measurement showed that the prepared cubosomes had a negative surface charge of −17.50 ± 0.45, indicating a highly stable nanodispersion formation with little susceptibility to particle aggregation. The cubosomal dispersion exhibited an entrapment efficiency of 88.57 ± 2.36%. The transmission electron micrograph for the prepared celecoxib-loaded cubosomes showed a narrow size distribution for the cubosomal nanoparticles, which had a spherical shape and were non-aggregated. The tested cubosomes diminished the inflammation in the treated mice’s liver and spleen tissues, as revealed by hematoxylin and eosin stain and Masson’s trichrome stain. The immunostained tissues with nuclear factor kappa B and caspase-3 monoclonal antibodies revealed a marked decrease in these markers in the celecoxib-treated group, as it resulted in negative or weak immunostaining in liver and spleen that ranged from 4.54% to 17.43%. This indicates their inhibitory effect on the inflammatory pathway and apoptosis, respectively. Furthermore, they reduced the bacterial burden in the studied tissues. This is alongside a decrease in the inflammatory markers (interleukin-1 beta, interleukin-6, cyclooxygenase-2, and tumor necrosis factor-alpha) determined by ELISA and qRT-PCR. The IL-1β levels were 16.66 ± 0.5 pg/mg and 17 ± 0.9 pg/mg in liver and spleen, respectively. Also, IL-6 levels were 85 ± 3.2 pg/mg and 84 ± 2.4 pg/mg in liver and spleen, respectively. In conclusion, the current study introduced cubosomes as an approach for the formulation of celecoxib to enhance its in vivo antibacterial action by improving its oral bioavailability.

Schlagwörter

Stichwörter der Autor:innen

bacterial infectionhistological featuresinflammatory markersnanostructuresoral delivery systemrepurposing

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
  • Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Helwan University, Cairo 11790, Egypt.
  • Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Mansoura 11152, Egypt.
  • Al-Taqaddom Pharmaceutical Industries, Amman 11947, Jordan.
  • Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.

ORCID-Profile: Mohamed Nasr, Ahmed Y Kira, Hadil Faris Alotaibi, Al-Sayed Sallam, Engy Elekhnawy

Förderung

  • Deanship of Scientific Research at Princess Nourah bint Abdulrahman University

Zitieren

APA

Alshawwa, S. Z., El-Masry, T. A., Nasr, M., Kira, A. Y., Alotaibi, H. F., Sallam, A. S., & Elekhnawy, E. (2023). Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach for Staphylococcus aureus In Vivo Infection. Microorganisms, 11(9), 2247. https://doi.org/10.3390/microorganisms11092247

Vancouver

Alshawwa SZ, El-Masry TA, Nasr M, Kira AY, Alotaibi HF, Sallam AS, et al. Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach for Staphylococcus aureus In Vivo Infection. Microorganisms. 2023;11(9):2247. doi:10.3390/microorganisms11092247

BibTeX
@article{Alshawwa2023,
  author = {Alshawwa, Samar Zuhair and El-Masry, Thanaa A and Nasr, Mohamed and Kira, Ahmed Y and Alotaibi, Hadil Faris and Sallam, Al-Sayed and Elekhnawy, Engy},
  title = {Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach for Staphylococcus aureus In Vivo Infection},
  journal = {Microorganisms},
  year = {2023},
  volume = {11},
  number = {9},
  pages = {2247},
  doi = {10.3390/microorganisms11092247}
}
Kostenlos starten →